address1,address2,city,zip,country,phone,website,industry,industryKey,industryDisp,sector,sectorKey,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,executiveTeam,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,tradeable,enterpriseValue,forwardPE,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,quoteType,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,symbol,language,region,typeDisp,quoteSourceName,triggerable,customPriceAlertConfidence,regularMarketChangePercent,regularMarketPrice,marketState,longName,shortName,hasPrePostMarketData,firstTradeDateMilliseconds,regularMarketChange,regularMarketDayRange,fullExchangeName,averageDailyVolume3Month,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekChangePercent,epsTrailingTwelveMonths,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeDataDelayedBy,cryptoTradeable,corporateActions,regularMarketTime,exchange,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,trailingPegRatio
World Trade Center Göteborg,"Mässans gata 10, floor 7",Gothenburg,412 51,Sweden,46 7 03 31 90 51,https://www.elicera.com,Biotechnology,biotechnology,Biotechnology,Healthcare,healthcare,Healthcare,"Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.",2,"[{'maxAge': 1, 'name': 'Mr. Jamal  El-Mosleh M.Sc.', 'age': 43, 'title': 'CEO & Co-Founder', 'yearBorn': 1981, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Prof. Magnus  Essand', 'age': 60, 'title': 'Chief Science Officer, Co-Founder & Director', 'yearBorn': 1964, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Di  Yu', 'age': 39, 'title': 'Co-Founder & Head of Transitional Research', 'yearBorn': 1985, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ingvar  Karlsson', 'age': 68, 'title': 'Chief Financial Officer', 'yearBorn': 1956, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Anna Koptina Gultekin', 'title': 'Head of Regulatory Affairs', 'exercisedValue': 0, 'unexercisedValue': 0}]",[],86400,2,5.5,5.42,5.4,5.64,5.5,5.42,5.4,5.64,0.0,0.443,116094,116094,464458,190219,190219,5.4,5.45,264518464,1.265,7.48,61.343136,5.4195,3.027025,0.0,0.0,SEK,False,245075136,54.499996,0.0,34243768,48535500,0.43958,0.02641,48535500,0.675,8.074074,1735603200,1767139200,1743379200,-18754112,-0.47,56.834,-12.563,2.4591196,0.12677538,EQUITY,5.45,6.4,6.4,6.4,6.4,none,1,45652772,0.941,-19508274,0,3.404,3.404,4312112,0.121,-0.27793,-0.58267,4312112,-8403005,-14943693,-0.928,1.0,0.0,-36.869827,SEK,ELIC.ST,en-US,US,Equity,Delayed Quote,True,HIGH,-0.9090944,5.45,CLOSED,Elicera Therapeutics AB (publ),Elicera Therapeutics AB,False,1623394800000,-0.05000019,5.4 - 5.64,Stockholm,464458,4.185,3.3083005,1.265 - 7.48,-2.0300002,-0.2713904,245.91196,-0.47,-0.3,-18.166666,0.030499935,0.0056278137,2.4229748,0.8004476,15,0,False,[],1751642972,STO,finmb_699501886,Europe/Stockholm,CEST,7200000,se_market,False,
